The difference between atilizumab and bevacizumab mainly includes different drug action principles, different adapted diseases and different adverse reactions.
1. Drug principle: atilizumab mainly promotes cell apoptosis to achieve the effect of tumor treatment, which is also known as immunotherapy. Bevacizumab inhibits tumor growth by inhibiting tumor angiogenesis.
2. Adaptation: Atilizumab is adapted to lung cancer, liver cancer and so on; Bevacizumab has more adaptations, such as lung cancer, ovarian cancer, head and neck malignant tumor, colorectal cancer, pancreatic cancer and so on.
3. Adverse reactions: Atelizumab belongs to immune drugs, which is prone to immune-related hepatitis, pneumonia, myocarditis, diarrhea, dermatitis and so on; Bevacizumab is often associated with hemorrhage, elevated blood pressure, skin rash and so on.
The use of drugs should be under the guidance of a doctor.